Which Impurity Reference Standards Are Needed for Empagliflozin Generic Development?
Empagliflozin (CAS 864070-44-0)is one of the best-selling SGLT2 inhibitors worldwide. As the patent expiry window approaches, the number of generic drug applications continues to grow both domestically and abroad. Impurity studies are the core part of generic drug registration, and choosing the right reference standards and covering the correct impurity types directly affects the application timeline and review conclusions. Starting from regulatory requirements and combining the structural characteristics and synthetic route of empagliflozin, this article outlines the impurity reference standard types that must be covered in generic development.
Empagliflozin
CAS No.:864070-44-0
1. Regulatory Framework: Which Impurities Must Have Reference Standards
According to ICH Q3A R2 (Impurities in New Drug Substances), impurities are managed in three tiers by threshold:
Reporting threshold: ≥0.05%, must be listed in the test report
Identification threshold: ≥0.10% (or daily intake >1.0 mg, whichever is stricter), structural identification must be completed
Qualification threshold: tiered by maximum daily dose; the maximum daily dose of empagliflozin is 25 mg, falling into the ">10 mg and ≤2 g/day" tier with a corresponding threshold of ≥0.2% or daily intake >2 mg (whichever is stricter), requiring limits in the specification and a safety assessment
In principle, impurities at or above the identification threshold all need reference standards with structural characterization. The domestic CDE requires systematic comparison of the impurity profiles of generics and the reference listed drug, covering all known specified impurities in the reference listed drug; the FDA likewise requires that the generic impurity profile be "comparable" to the innovator in ANDA review. The core logic of the two is consistent, and the same impurity study data package can be shared when filing simultaneously domestically and abroad.
2. Where Do Empagliflozin Impurity Risks Come From
The core structure of empagliflozin is a β-C-glucoside skeleton bearing a side chain containing a chlorophenyl group and a tetrahydrofuran ether. This structure determines three main categories of impurity risk:
Stereoisomers are the primary concern. The anomeric carbon configuration of the C-glucoside directly determines drug activity; the α-anomer is an unavoidable byproduct of synthesis and must be individually limited as a specified impurity, requiring a dedicated reference standard for identification and quantification.
Synthetic process impurities are the second largest source. The industrial synthetic route of empagliflozin involves carbon-carbon bond construction with iodine-containing aryl compounds; if the related iodinated intermediates and their derivatives are not fully removed in subsequent purification, they will remain in the API as process impurities. These impurities retain iodine atoms in their structures, have molecular weights significantly lower than the API, and show markedly different chromatographic behavior, requiring dedicated reference standards for identification and quantification.
Oxidative degradation impurities are the third largest source. The multiple secondary hydroxyl groups on the glucose ring can form more highly oxygenated degradation products under oxidative stress. ICH Q1A R2 stability studies require systematic investigation of degradation behavior under accelerated and forced degradation conditions, and the corresponding degradation impurity reference standards are essential support for stability protocols.
3. Essential Impurity Reference Standard List
Based on synthetic route analysis and published pharmacopoeial information, generic development of empagliflozin usually needs to cover the following items (the list below only shows some of the in-stock items available from CATO; the reference standards actually required should be based on the company's own process route and impurity profile analysis)
The isotope-labeled internal standard (deuterated d4) can effectively eliminate matrix effects in LC-MS/MS methods and is suitable for plasma concentration determination and formulation content uniformity testing, serving as the standard configuration for high-precision quantitative analysis.
4. Quality Requirements for Reference Standards
Impurity reference standards used for generic drug applications must meet the following quality conditions:
Purity: ≥95% (HPLC area normalization), with key specified impurities recommended at ≥98%
Value assignment: provide absolute content assignment (e.g., qNMR or mass balance method) rather than reporting only chromatographic purity
Traceability: content values traceable to SI units, meeting ISO 17034 certification requirements
Certificate completeness: the COA must include structural confirmation data (NMR, MS) and assay results
CATO (Guangzhou CATO Research Chemicals Co., Ltd.) holds ISO 17034 certification issued by both CNAS and ANAB. The above empagliflozin series products all come with complete COAs with traceable value assignment, directly supporting domestic generic drug registration (CDE consistency evaluation) and method development and validation for overseas ANDA/NDA applications.